Wednesday, December 06, 2017 5:22:39 PM
NASH drug developers in the red after Madrigal's mid-stage success with MGL-3196
Dec. 6, 2017 12:37 PM ET|By: Douglas W. House, SA News Editor
Investors are swarming over Madrigal Pharmaceuticals (MDGL +79.8%) after it reported positive results from a Phase 2 clinical trial assessing MGL-3196 in NASH patients. Certain would-be NASH players have been brushed aside in early trading.
Selected tickers: (MNOV +0.9%)(GLMD)(RGLS -2.2%)(ICPT +0.4%)(CNAT -2.4%)(VBLT +1.6%)(GALT -8.7%)(SHPG -1.5%)(AGN +0.3%)(HZNP -1.2%)(OTCPK:GNFTF -5%)(VKTX +2.6%)
I'm not familiar with MDGL's entry...whether it's a targeted approach for a single issue (NASH), or a multi-faceted potential like CNAT. CNAT's game is for combination therapies focused on multiple liver issues not exclusively NASH.
From CNAT Website:
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM